Stock Ratings / Health Care / HCM / options

RCUS (35) PGEN (35) PHVS (63) SUPN (56) ⌘ Pro Terminal →

HUTCHMED (China) Limited (HCM) Options Positioning, Max Pain & Unusual Sweeps

$13.59 +2.03% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

HUTCHMED (China) Limited (HCM) carries a Roarable Rating of D (Sell) with 46/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $2.37B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk C-

Each axis scored 0–20

12M PRICE TARGET CONE-5.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for HCM)Realized 20D OHLCV Swing Band: ±5.6%

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±5.6%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (HCM)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for HCM.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring HCM)

✓Walkthrough of HCM's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

HCM // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +1.12%🛡️ HOLDING TREND SUPPORT

2026-10-30O $13.35H $13.59L $13.14C $13.59VOL 33.5K

RES: $16.54SUP: $13.20SMA50: $13.65SMA200: $13.22

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

HCM Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 HCM Butterfly Map → + Track HCM →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

-13.3%/yr Implied 5Y Growth

vs. -13.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on HCM today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for HCM. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for HCM today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (HCM)

Health Care Rank #439 of 1016 ⚔️ RCUS vs HCM Full Matrix →

1. Head-to-Head Health Care Peer Comparison (HCM vs. RCUS, PGEN, PHVS, SUPN)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, HUTCHMED (China) Limited (HCM) ranks #439 by composite RQD confidence (46/100, grade D) and #227 by equity capitalization ($2.37B). Within this direct 5-issuer industry benchmark cohort, HCM leads on earnings valuation at 5.2x trailing P/E, while HCM leads on capital efficiency and profitability with -2.5% ROIC and — gross margin. PHVS currently holds the highest overall quantitative score in the immediate peer group at 63/100 (C) compared with HCM at 46/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
HCM ACTIVE HUTCHMED (China) Limited	D	46/100	5.2x	—	-2.5%	+2.03%	$2.37B	Benchmark Subject
RCUS Arcus Biosciences Inc.	D-	35/100	—	—	-35.0%	+1.20%	$2.37B	/rcus-vs-hcm →
PGEN Precigen Inc.	D-	35/100	—	—	-35.0%	+9.21%	$2.38B	/pgen-vs-hcm →
PHVS Pharvaris N.V.	C	63/100	—	—	—	+2.32%	$2.34B	/phvs-vs-hcm →
SUPN Supernus Pharmaceuticals Inc.	D+	56/100	—	89.6%	-4.5%	+1.85%	$2.43B	/supn-vs-hcm →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001648257

In its most recent audited fiscal period (FY2025, filed 2025-12-31), HUTCHMED (China) Limited (HCM) reported GAAP revenue of $548.5M (-13.0% vs. FY2024 revenue of $630.2M , and -34.5% cumulative change since FY2023) , GAAP net income of $456.9M, operating cash flow of -$64.7M, and free cash flow of -$78.8M (-352.0% YoY). On the balance sheet, HCM closed FY2025 with $1.75B in total assets against $68.2M in total debt (Altman Z-Score: 3.63, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$548.5M	$456.9M	-$64.7M	-$78.8M	$1.75B	$68.2M
FY2024 (FY)	2024-12-31	$630.2M	$37.7M	$497.0K	-$17.4M	$1.27B	$59.4M
FY2023 (FY)	2023-12-31	$838.0M	$100.8M	$219.3M	$219.3M	—	—

3. HCM Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is HCM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, HUTCHMED (China) Limited (NASDAQ: HCM) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $13.59 (+2.03% 1D, market cap $2.37B). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 12/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 7/20. Across 1016 tracked Health Care issuers, HCM ranks #439 in composite RQD confidence.

How does HCM compare to RCUS and PGEN in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), HCM carries a Roarable D (46/100 RQD), trailing P/E of 5.2x, gross margin of —, and ROIC of -2.5%. By comparison, RCUS (Arcus Biosciences Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $2.37B) and PGEN (Precigen Inc.) posts a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $2.38B). Among the 5-stock peer group, HCM leads on earnings multiple (5.2x) while HCM leads on capital efficiency (-2.5% ROIC).

What are the biggest fundamental strengths and SEC risk factors for HCM?

Per HCM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001648257), HUTCHMED (China) Limited generated $548.5M in revenue (-13.0% YoY), $456.9M in net income, and -$78.8M in free cash flow against $1.75B in total assets and $68.2M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is HCM trading relative to its 50-day, 200-day, and 52-week technical levels?

HCM last traded at $13.59 (+2.03% on volume of 34,280 shares), positioning the stock -0.44% below its 50-day simple moving average ($13.65) and +2.80% above its 200-day simple moving average ($13.22). Across its 52-week range of $9.77 to $16.33, HCM sits at the 58.2% percentile with a 14-day RSI of 41.1 (NEUTRAL RANGE) and an implied next-earnings move of ±5.6% ($12.83 to $14.35).

HCM Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is HCM's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for HCM.

Direct Sub-Reports: HCM RQD Cockpit HCM 12M Forecast HCM Earnings & Move HCM Dividends & DRIP HCM Insiders & 13F HCM Whale Options HCM Profit Sankey HCM News & Why